Akesogen, Inc.

Tempus Labs, Inc.

UEI
DCNEWAMUCPB4
CAGE
6FRL1
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Website
tempus.com
Founded
2015
Employees
1K-5K
Estimated annual revenue
$500M-$1B
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $4,000,000
FY2024 $3,999,942
FY2023 $6,150,616

Contract awards

Award Agency Obligated Awarded
Genomic analysis 36C24E25N0255 Veterans Integrated Service Network 4 (VHA) $4,000,000
Genomic analysis 36C24E24N0168 Veterans Integrated Service Network 4 (VHA) $4,000,000
Genomic analysis 36C24E23N0238 Veterans Integrated Service Network 4 (VHA) $6,400,000
Genomic analysis 36C24E22N0189 Veterans Integrated Service Network 4 (VHA) $13,020,379
Genomic analysis 36C24E21N0180 Veterans Integrated Service Network 4 (VHA) $10,477,739

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

About the company

Akesogen, Inc., operating through its Tempus Labs, Inc. division, is a for-profit corporate entity registered in SAM.gov since 2011, specializing in advanced genomic analysis and molecular research services. The company is primarily focused on providing sophisticated scientific and technological services to federal agencies, with a significant concentration on biomedical research initiatives. Although specific details about the company's broader corporate profile are not available in the provided documentation, its primary federal contract work is centered on genomic research and analysis.

Akesogen, Inc.'s Tempus Labs, Inc. division has exclusively performed genomic analysis services for the U.S. Department of Veterans Affairs (VA) Headquarters through a series of firm fixed-price delivery order contracts. These contracts are part of a larger $111 million Indefinite Delivery Contract (IDC) awarded in 2020, supporting the VA's Million Veteran Program. The company's services include genomic sequencing, DNA quality assessment, single nucleotide polymorphism genotyping, methylation analysis, and other molecular testing services. The contract awards, ranging from $4 million to $13 million, have been consistently non-set-aside and focused on supporting biomedical research involving the analysis of over 800,000 veteran DNA samples. The work is performed at VA Headquarters in Washington, D.C., with contract periods typically spanning two years and completion dates ranging from September 2022 to March 2026.

Quick answers

Is Akesogen, Inc. registered in SAM.gov?

Akesogen, Inc.'s SAM.gov registration expired on July 24, 2024.

How much has Akesogen, Inc. received in federal contracts?

Federal contracts obligated $4,000,000 to Akesogen, Inc. in fiscal year 2025 and $14,150,558 in fiscal years 2023 through 2027.

How does Akesogen, Inc. rank among federal contractors?

Akesogen, Inc. ranked #22 in PSC Q3 and #32 in NAICS 54138 in FY2025.

What is Akesogen, Inc.'s most recent federal award?

Akesogen, Inc.'s most recent federal contract award is Genomic analysis (36C24E25N0255), from Veterans Integrated Service Network 4 (VHA), on September 30, 2025.

On GovTribe

See Akesogen, Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors